The IMMP1L Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated in the Jurkat human T-lymphocyte line to disrupt the IMMP1L gene. IMMP1L encodes a putative catalytic subunit of the mitochondrial inner membrane peptidase complex that processes nuclear-encoded mitochondrial precursor proteins. This polyclonal population provides a heterogeneous loss-of-function model for studying IMMP1L in T-cell biology.
Jurkat cells are a widely used model derived from an acute lymphoblastic leukemia patient, exhibiting robust T-cell signaling and apoptosis pathways. Their immortalized nature facilitates genetic manipulation, and their suspension growth enables high-throughput functional assays, rendering them ideal for exploring mitochondrial-regulated processes in adaptive immunity.
IMMP1L functions as a component of the inner membrane peptidase complex, interacting with IMMP2L, IMMP1, PMPCA, and PMPCB to cleave sorting signals from precursors imported via TIM23 translocase. This processing is critical for oxidative phosphorylation complex assembly. IMMP1L expression is controlled by transcription regulators PGC1??, NRF1, TFAM, and estrogen-related receptor alpha. Disruption of IMMP1L likely impairs precursor maturation, leading to defective respiratory chain function, increased cytochrome c release, and caspase-dependent apoptosis in Jurkat cells.
In Jurkat T cells, mitochondrial proteostasis is vital for energy production during activation and cytokine secretion, as well as for regulating intrinsic apoptosis. IMMP1L knockout may perturb these processes, offering a model to study how inner membrane peptidase dysfunction affects T-cell survival and leukemic growth. This makes it a valuable tool for investigating mitochondrial contributions to T-cell acute lymphoblastic leukemia and for identifying mitochondrial vulnerabilities in malignant T cells.
This knockout product is suited for experiments assessing mitochondrial protein processing, mitochondrial membrane potential (JC-1), apoptosis (Annexin V/PI flow cytometry), cytochrome c release, and transcriptomic profiling by RT-qPCR and RNA-seq. It enables functional dissection of IMMP1L in T-cell activation and leukemia, and can be used to screen mitochondrial-targeting compounds. For additional information, contact Ascent Research.
